Supernus Pharmaceuticals (SUPN) Share-based Compensation (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Share-based Compensation of $8.6 million for Q2 2026, up 15.09% year-over-year from $7.5 million in Q2 2025, and up 1.89% on a QoQ basis from $8.5 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Share-based Compensation (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Share-based Compensation for 16 years, with the latest figure at $8.6 million in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $8.6 million, up 15.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $34.6 million (up 12.03% YoY), and the FY2025 annual result was $33.1 million, up 19.08% from the prior year.
- Share-based Compensation rose to $8.6 million in Q2 2026, from $8.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $9.7 million in Q4 2025 and troughed at $4.0 million in Q1 2022.
- A 5-year average of $6.8 million and a median of $7.0 million in 2024 frame the typical range for Share-based Compensation.
- The widest annual swing landed in 2022, when Share-based Compensation decreased 21.53%; it then soared 58.88% in 2023.
- A 5-year view of Share-based Compensation shows it stood at $4.3 million in 2022, then surged by 51.26% to $6.4 million in 2023, then advanced by 18.42% to $7.6 million in 2024, then rose by 26.45% to $9.7 million in 2025, then slipped by 10.48% to $8.6 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $8.6 million in Q2 2026, $8.5 million in Q1 2026, and $9.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | 8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.64 Mn |
| Jun 30, 2026 | 8.64 Mn |
| Mar 31, 2026 | 4.56 Mn |
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 28.85 Mn |
| Dec 31, 2025 | 28.85 Mn |
| Sep 30, 2025 | 811,000.00 |
| Sep 30, 2025 | 811,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 3.34 Mn |
| Mar 31, 2025 | 3.34 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Sep 30, 2024 | 7.67 Mn |
| Sep 30, 2024 | 7.67 Mn |
| Jun 30, 2024 | 9.85 Mn |
| Jun 30, 2024 | 9.85 Mn |
| Mar 31, 2024 | 2.60 Mn |
| Mar 31, 2024 | 2.60 Mn |